^
    Back
    Association details:
    Biomarker:BCR-ABL1 E255K
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:S81694 (TTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

    Published date:
    11/06/2019
    Excerpt:
    S81694 induced significant apoptosis (70%) in the imatinib resistant BV173 cell line bearing the E255K-BCR-ABL1 mutation.
    DOI:
    https://doi.org/10.1182/blood-2019-125641